Topic is suspended
Status Suspended
Decision Selected
Process TAG
ID number 2702


Key events during the development of the guidance:

Date Update
26 February 2021 Suspended. Topic is suspended
26 February 2021 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application at this time, from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
24 January 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual